Showing 1 - 16 results of 16 for search 'Renard, C.', query time: 0.05s Refine Results
  1. 1
    Adaptation du riz pluvial au déficit hydrique

    Adaptation du riz pluvial au déficit hydrique by Renard, C.

    Published 1983-01-01
    Get full text
    Article
  2. 2
    Comportement de Stylosanthes guianensis (Aubl.) Sw. dans la basse Ruzizi et le Mosso (Burundi)

    Comportement de Stylosanthes guianensis (Aubl.) Sw. dans la basse Ruzizi et le Mosso (Burundi) by Vancoppenolle, R., Renard, C., Sottiaux, G., Nyole, H.

    Published 1984-01-01
    Get full text
    Article
  3. 3
    Support for single major genes influencing fat androstenone level and development of bulbo-urethral glands in young boars

    Support for single major genes influencing fat androstenone level and development of bulbo-urethral glands in young boars by Sellier P, Renard C, Gruand J, Le Roy P, Fouilloux MN, Bonneau M

    Published 1997-07-01
    Get full text
    Article
  4. 4
    Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.

    Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. by Scott F Winter, Luanne Lukes, Renard C Walker, Danny R Welch, Kent W Hunter

    Published 2012-05-01
    Get full text
    Article
  5. 5
    AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)

    AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment... by Vyas, P, Daver, N, Chao, M, Xing, G, Renard, C, Ramsingh, G, Sallman, D

    Published 2022
    Conference item
  6. 6
    Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.

    Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. by Farhoud Faraji, Yanli Pang, Renard C Walker, Rosan Nieves Borges, Li Yang, Kent W Hunter

    Published 2012-09-01
    Get full text
    Article
  7. 7
    A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia

    A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acut... by Vyas, P, Daver, N, Chao, M, Xing, G, Renard, C, Ramsingh, G, Wei, AH, Sallman, DA

    Published 2021
    Conference item
  8. 8
    A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia

    A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute mye... by Daver, N, Vyas, P, Chao, MP, Xing, G, Renard, C, Ramsingh, G, Sallman, DA, Wei, AH

    Published 2022
    Conference item
  9. 9
    A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia

    A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute mye... by Daver, N, Vyas, P, Chao, M, Xing, G, Renard, C, Ramsingh, G, Sallman, DA, Wei, AH

    Published 2021
    Conference item
  10. 10
    Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments.

    Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. by Ying Hu, Ling Bai, Thomas Geiger, Natalie Goldberger, Renard C Walker, Jeffery E Green, Lalage M Wakefield, Kent W Hunter

    Published 2013-01-01
    Get full text
    Article
  11. 11
    Functional analysis of prognostic gene expression network genes in metastatic breast cancer models.

    Functional analysis of prognostic gene expression network genes in metastatic breast cancer models. by Thomas R Geiger, Ngoc-Han Ha, Farhoud Faraji, Helen T Michael, Loren Rodriguez, Renard C Walker, Jeffery E Green, R Mark Simpson, Kent W Hunter

    Published 2014-01-01
    Get full text
    Article
  12. 12
    Deciphering the causes of the COSMIC mutational signature 17 by combining pan-cancer data with experimental mouse models

    Deciphering the causes of the COSMIC mutational signature 17 by combining pan-cancer data with experimental mouse models by Tomkova, M, Renard, C, Urban, L, Kolli, S, Ardin, M, Pandey, M, Zhivagui, M, Huskova, H, Olivier, M, Marusawa, H, Schuster-Boeckler, B, Zavadil, J

    Published 2019
    Conference item
  13. 13
    Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.

    Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. by Nigel P S Crawford, Xiaolan Qian, Argyrios Ziogas, Alex G Papageorge, Brenda J Boersma, Renard C Walker, Luanne Lukes, William L Rowe, Jinghui Zhang, Stefan Ambs, Douglas R Lowy, Hoda Anton-Culver, Kent W Hunter

    Published 2007-11-01
    Get full text
    Article
  14. 14
    AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results

    AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML)... by Daver, N, Vyas, P, Kambhampati, S, Malki, MA, Larson, R, Asch, A, Mannis, G, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, E, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, J, Sallman, D

    Published 2022
    Conference item
  15. 15
    Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

    Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, GN, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, JF, Sallman, DA

    Published 2022
    Journal article
  16. 16
    BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane.

    BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane. by Jude Alsarraj, Farhoud Faraji, Thomas R Geiger, Katherine R Mattaini, Mia Williams, Josephine Wu, Ngoc-Han Ha, Tyler Merlino, Renard C Walker, Allen D Bosley, Zhen Xiao, Thorkell Andresson, Dominic Esposito, Nicholas Smithers, Dave Lugo, Rab Prinjha, Anup Day, Nigel P S Crawford, Keiko Ozato, Kevin Gardner, Kent W Hunter

    Published 2013-01-01
    Get full text
    Article

Search Tools: